Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study. için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study. | 1 |
Aylık toplam ziyaret
| views | |
|---|---|
| Aralık 2025 | 0 |
| Ocak 2026 | 0 |
| Şubat 2026 | 0 |
| Mart 2026 | 0 |
| Nisan 2026 | 0 |
| Mayıs 2026 | 0 |
| Haziran 2026 | 0 |
